<?xml version="1.0" encoding="UTF-8"?>
<p>It was planned to recruit 600 patients to the everolimus randomization, which would have given 85% power to detect a 12.5% difference in the primary endpoint of relapse-free survival, from 50% to 62.5% (HR 0.68). Follow-up is complete until March 1
 <sup>st</sup>, 2016 [median follow-up from diagnosis 53.5 months (range, 4.3 â€“ 76.8 months)].
</p>
